MedTrace Logo

Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A

NCT00000116 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 221

Last updated 2023-03-08

No results posted yet for this study

Summary

The purpose of this trial is to determine whether a nutritional supplement in addition to vitamin A will slow the course of retinitis pigmentosa.

Conditions

Interventions

DIETARY_SUPPLEMENT

Vitamin A

15000 IU/d as retinyl palmitate

DIETARY_SUPPLEMENT

Docosahexaenoic acid

1200 mg/d

DIETARY_SUPPLEMENT

Control fatty acid

Sponsors & Collaborators

  • Carol Weigel DiFranco

    lead NIH

Principal Investigators

  • Eliot Berson (Deceased), MD · Berman-Gund Laboratory for the Study of Retinal Degenerations, Harvard Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1996-05-31
Primary Completion
2002-09-30
Completion
2002-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000116 on ClinicalTrials.gov